Chemotherapy-induced peripheral neuropathy research: a National Institutes of Health (NIH) grant portfolio analysis (2014-2023)
JNCI Cancer Spectrum · 2025
DOI: 10.1093/jncics/pkaf039 ↗Kurz gefasst
Fachartikel in der Zeitschrift JNCI Cancer Spectrum, 2025. Verfasst von Rachel D Altshuler und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Rockville, MD, United States. Hauptthemen laut MEDLINE: Peripheral Nervous System Diseases, Antineoplastic Agents, Research Support as Topic, Biomedical Research. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Chemotherapy-induced peripheral neuropathy (CIPN) is a debilitating acute and long-term toxicity in cancer patients. We sought to describe the landscape of CIPN research funded by the National Institutes of Health (NIH) and identify gaps and opportunities.
Methods
Using the NIH Query View Report system, we identified 180 competitive grants between 2014-2023 containing text pertaining to CIPN in the Abstract or Specific Aims. These were categorized as preclinical, clinical, or both and described by preclinical model, clinical population, CIPN assessments, and/or clinical trial design. We identified 5 additional NCI-funded trials through the NCORP network pertaining to CIPN.
Results
Of 185 studies, 125 were preclinical, 56 clinical, and 4 both preclinical/clinical. Among preclinical studies, most studies used rodent CIPN models, of which 17% were tumor-bearing. Most preclinical studies investigated paclitaxel; none studied newer immune therapies. The 60 clinical studies were 53% observational and 47% interventional, focusing most frequently on breast cancer, unspecified cancers, and colorectal cancer diagnoses. Overall, 8% included patients <18 years, whereas a higher proportion included those 18-39 (85%), 40-64 (90%), and ≥65 (92%). Among 28 interventional trials, studies investigated behavioral interventions (39%), pharmacological agents (32%), and devices (29%).
Conclusions
The number of CIPN grants awarded by NIH since 2014 represents a substantial investment, but critical gaps and opportunities remain. Preclinically, novel strategies to mimic human CIPN may improve translatability. Important gaps in CIPN-associated cancer diagnoses and therapy exposures, including novel agents, would benefit from future research. Also, clinical studies are needed in young patients with potential long-term CIPN.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Rockville, MD, United States.
- Department of Oncology Cancer Prevention and Control Program, Georgetown University Lombardi Comprehensive Cancer Center, Washington, DC, United States.
ORCID-Profile: Rachel D Altshuler, Lori M Minasian, Catherine A Schweppe, Nina S Kadan-Lottick
Zitieren
APA
Altshuler, R. D., Minasian, L. M., Schweppe, C. A., & Kadan-Lottick, N. S. (2025). Chemotherapy-induced peripheral neuropathy research: a National Institutes of Health (NIH) grant portfolio analysis (2014-2023). JNCI Cancer Spectrum. https://doi.org/10.1093/jncics/pkaf039
Vancouver
Altshuler RD, Minasian LM, Schweppe CA, Kadan-Lottick NS. Chemotherapy-induced peripheral neuropathy research: a National Institutes of Health (NIH) grant portfolio analysis (2014-2023). JNCI Cancer Spectrum. 2025. doi:10.1093/jncics/pkaf039
BibTeX
@article{Altshuler2025,
author = {Altshuler, Rachel D and Minasian, Lori M and Schweppe, Catherine A and Kadan-Lottick, Nina S},
title = {Chemotherapy-induced peripheral neuropathy research: a National Institutes of Health (NIH) grant portfolio analysis (2014-2023)},
journal = {JNCI Cancer Spectrum},
year = {2025},
doi = {10.1093/jncics/pkaf039}
}
EUVIMED